Ecor1 Capital, Llc Buys 19,748 Shares of Zymeworks Inc. (NYSE:ZYME) Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 19,748 shares of the business’s stock in a transaction dated Friday, January 17th. The shares were purchased at an average price of $13.87 per share, with a total value of $273,904.76. Following the transaction, the director now owns 15,720,161 shares of the company’s stock, valued at approximately $218,038,633.07. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 15th, Ecor1 Capital, Llc purchased 39,029 shares of Zymeworks stock. The shares were purchased at an average cost of $14.01 per share, with a total value of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc acquired 74,125 shares of Zymeworks stock. The stock was purchased at an average cost of $13.39 per share, for a total transaction of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The shares were purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc purchased 21,021 shares of Zymeworks stock. The stock was acquired at an average price of $14.07 per share, for a total transaction of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 157,880 shares of Zymeworks stock. The shares were acquired at an average price of $14.78 per share, with a total value of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The stock was acquired at an average price of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc purchased 11,958 shares of Zymeworks stock. The stock was bought at an average price of $14.12 per share, with a total value of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc acquired 16,692 shares of Zymeworks stock. The shares were bought at an average price of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Trading Up 3.0 %

Shares of NYSE ZYME traded up $0.41 during mid-day trading on Tuesday, reaching $14.29. The company had a trading volume of 277,027 shares, compared to its average volume of 516,107. The stock has a market cap of $984.30 million, a price-to-earnings ratio of -9.53 and a beta of 1.10. Zymeworks Inc. has a 52 week low of $7.97 and a 52 week high of $17.70. The business’s 50-day moving average is $14.24 and its 200-day moving average is $12.71.

Zymeworks (NYSE:ZYME) last issued its earnings results on Thursday, October 31st. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business had revenue of $16.00 million for the quarter, compared to analyst estimates of $17.90 million. During the same period last year, the company posted ($0.41) earnings per share. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. As a group, equities research analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Citigroup lifted their target price on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, November 4th. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price objective on shares of Zymeworks in a research note on Friday, November 22nd. Wells Fargo & Company increased their target price on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Leerink Partners raised shares of Zymeworks from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $10.00 to $25.00 in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective on the stock in a research report on Monday, December 16th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.17.

Hedge Funds Weigh In On Zymeworks

Several institutional investors have recently made changes to their positions in ZYME. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Zymeworks by 0.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company’s stock worth $24,416,000 after acquiring an additional 14,604 shares in the last quarter. Perceptive Advisors LLC lifted its position in shares of Zymeworks by 55.2% in the 2nd quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company’s stock worth $14,192,000 after purchasing an additional 592,904 shares during the period. State Street Corp lifted its position in shares of Zymeworks by 6.1% in the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after purchasing an additional 67,401 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Zymeworks by 127.5% during the second quarter. Dimensional Fund Advisors LP now owns 715,632 shares of the company’s stock valued at $6,090,000 after purchasing an additional 401,068 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Zymeworks by 93.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 642,251 shares of the company’s stock valued at $9,403,000 after buying an additional 311,107 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.